REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights
ROCKVILLE, Md., Aug. 6, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today reported financial results and operational highlights for the second quarter ended June 30, 2026.
"Our second quarter was defined by strong clinical execution across our pipeline: the Phase III AFFINITY DUCHENNE ® trial met its primary endpoint, we dosed the first participant in the NAAVIGATE study in diabetic retinopathy, and the FDA reaffirmed the path forward for RGX-121," said Curran Simpson, President and Chief Executive Officer of REGENXBIO. "With this progress and our strong cash runway, we are well positioned to deliver against multiple near-term, high-value catalysts, including the initiation of the RGX-202 BLA this quarter and wet AMD pivotal data in the coming months, as we advance potentially transformative gene therapies to patients."
Corporate Updates
PROGRAM HIGHLIGHTS AND MILESTONES
Neuromuscular Disease: RGX-202 is a potential best-in-class gene therapy for Duchenne muscular dystrophy (Duchenne). RGX-202 is designed to address the underlying cause of Duchenne by enabling targeted expression of a novel microdystrophin that is closest to naturally occurring dystrophin. The differentiated therapeutic approach behind RGX-202 includes a novel construct, with the C-Terminal domain, a proactive immune suppression regimen, and a suspension-based manufacturing process that delivers industry-leading product purity levels. RGX-202 is designed for improved muscle function, durability and positive safety outcomes and is being evaluated in the Phase I/II/III AFFINITY DUCHENNE ® trial and confirmatory trial in ambulatory patients aged 1+.
Retinal Disease: Surabgene lomparvovec (sura-vec, ABBV-RGX-314), developed in collaboration with AbbVie, is potentially the first-in-class gene therapy treatment for wet age-related macular degeneration (wet AMD) and diabetic retinopathy (DR).
Sura-vec for the Treatment of Wet AMD (Subretinal Delivery)
Sura-vec for the Treatment of DR (Suprachoroidal Delivery)
Neurodegenerative Disease: NAVSUNLI™ (clemidsogene lanparvovec, RGX-121) is a potential first-in-class treatment for MPS II, also known as Hunter syndrome, being developed and potentially commercialized in partnership with Nippon Shinyaku.
FINANCIAL RESULTS
Cash Position: Cash, cash equivalents and marketable securities were $105.5 million as of June 30, 2026, compared to $240.9 million as of December 31, 2025. The decrease was primarily driven by cash used to fund operating activities during the first half of 2026. In July 2026, REGENXBIO received a $100 million milestone payment from AbbVie for the dosing of the first patient in the Phase IIb/III NAAVIGATE study and approximately $108 million estimated net proceeds from an underwritten public offering of common stock and pre-funded warrants. Pro forma cash, cash equivalents and marketable securities as of June 30, 2026 was approximately $313 million, including the impact of the milestone payment and offering proceeds received in July 2026.
Revenues: Revenues were $108.0 million for the three months ended June 30, 2026, compared to $21.4 million for the three months ended June 30, 2025. The increase was primarily attributable to the $100.0 million development milestone achieved in the second quarter of 2026 upon dosing the first patient in the NAAVIGATE study. The increase was partially offset by a $16.7 million decrease in ZOLGENSMA ® royalty revenues due to the expiration of licensed patents in the U.S. in January 2026. Novartis launched U.S. sales of ITVISMA ® in the first quarter of 2026. ITVISMA is now also approved in the UAE, Japan, Qatar and the EU. REGENXBIO is entitled to royalties on certain net sales of ITVISMA in the U.S. and other jurisdictions with patents extending until 2037.
Research and Development (R&D) Expenses: R&D expenses were $56.1 million for the three months ended June 30, 2026, compared to $59.5 million for the three months ended June 30, 2025. The decrease was primarily attributable to manufacturing-related expenses and clinical trial expenses for sura-vec and NAVSUNLI pivotal trials.
General and Administrative Expenses: General and administrative expenses were $21.6 million for the three months ended June 30, 2026, compared to $19.9 million for the three months ended June 30, 2025. The increase was largely driven by personnel-related costs, commercialization expenses, consulting and other corporate advisory services.
Net Income: Net income was $22.7 million, or $0.43 basic and diluted net income per share, for the three months ended June 30, 2026, compared to net loss of $70.9 million, or $1.38 basic and diluted net loss per share, for the three months ended June 30, 2025.
FINANCIAL GUIDANCE
REGENXBIO expects its balance in cash, cash equivalents and marketable securities of $105.5 million as of June 30, 2026, along with the $100.0 million milestone payment and $107.8 million estimated net offering proceeds received in July 2026, are sufficient to fund operations into Q4 2027. This cash runway guidance is based on the Company's current operational plans and excludes the impact of any material payments that may potentially be received from partners or licensees upon the achievement of development or regulatory milestones, or upon the approval or commercialization of product candidates, and excludes any additional potential dilutive or non-dilutive funding opportunities.
CONFERENCE CALL
In connection with this announcement, REGENXBIO will host a conference call and webcast at 8:00 a.m. ET today. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.
ABOUT REGENXBIO Inc.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie, and NAVSUNLI™ (clemidsogene lanparvovec-sngl, RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA ®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit www.REGENXBIO.com.
FORWARD-LOOKING STATEMENTS
This press release includes "forward-looking statements," within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements express a belief, expectation or intention and are generally accompanied by words that convey projected future events or outcomes such as "believe," "may," "will," "estimate," "continue," "anticipate," "assume," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would" or by variations of such words or by similar expressions. The forward-looking statements include statements relating to, among other things, REGENXBIO's future operations, clinical trials, costs and cash flow. REGENXBIO has based these forward-looking statements on its current expectations and assumptions and analyses made by REGENXBIO in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors REGENXBIO believes are appropriate under the circumstances. However, whether actual results and developments will conform with REGENXBIO's expectations and predictions is subject to a number of risks and uncertainties, including the timing of enrollment, commencement and completion and the success of clinical trials conducted by REGENXBIO, its licensees and its partners, the timing of commencement and completion and the success of preclinical studies conducted by REGENXBIO and its development partners, the timing or likelihood of payments from AbbVie or Nippon Shinyaku, the monetization of any priority review voucher, the timely development and launch of new products, the ability to obtain and maintain regulatory approval of product candidates, the ability to obtain and maintain intellectual property protection for product candidates and technology, trends and challenges in the business and markets in which REGENXBIO operates, the size and growth of potential markets for product candidates and the ability to serve those markets, the rate and degree of acceptance of product candidates, and other factors, many of which are beyond the control of REGENXBIO. Refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of REGENXBIO's Annual Report on Form 10-K for the year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (SEC) and comparable "risk factors" sections of REGENXBIO's Quarterly Reports on Form 10-Q and other filings, which have been filed with the SEC and are available on the SEC's website at WWW.SEC.GOV. All of the forward-looking statements made in this press release are expressly qualified by the cautionary statements contained or referred to herein. The actual results or developments anticipated may not be realized or, even if substantially realized, they may not have the expected consequences to or effects on REGENXBIO or its businesses or operations. Such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Readers are cautioned not to rely too heavily on the forward-looking statements contained in this press release. These forward-looking statements speak only as of the date of this press release. Except as required by law, REGENXBIO does not undertake any obligation, and specifically declines any obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Zolgensma ® and Itvisma ® are registered trademarks of Novartis Gene Therapies. All other trademarks referenced herein are registered trademarks of REGENXBIO.
CONTACTS:
Dana Cormack
Corporate Communications
[email protected]
George E. MacDougall
Investor Relations
[email protected]
REGENXBIO INC.
CONSOLIDATED BALANCE SHEETS
(unaudited)
(in thousands)
June 30, 2026
December 31, 2025
Assets
Current assets
Cash and cash equivalents
$
36,487
$
34,466
Marketable securities
69,030
195,604
Accounts receivable
106,754
26,379
Prepaid expenses
11,904
11,927
Restricted cash
225
—
Other current assets
11,757
12,905
Total current assets
236,157
281,281
Marketable securities
—
10,785
Accounts receivable
435
2,312
Property and equipment, net
98,452
104,855
Operating lease right-of-use assets
43,867
47,156
Restricted cash
1,805
2,030
Other assets
5,902
4,613
Total assets
$
386,618
$
453,032
Liabilities and Stockholders' Equity
Current liabilities
Accounts payable
$
15,546
$
21,358
Accrued expenses and other current liabilities
23,073
38,390
Deferred revenue
9,882
10,452
Operating lease liabilities
7,355
8,286
Royalty monetization liabilities
26,765
39,609
Total current liabilities
82,621
118,095
Deferred revenue
15,404
18,943
Operating lease liabilities
61,596
65,215
Royalty monetization liabilities
154,746
147,408
Other liabilities
486
638
Total liabilities
314,853
350,299
Stockholders' equity
Preferred stock; no shares issued and outstanding
at June 30, 2026 and December 31, 2025
—
—
Common stock; 54,164 and 50,892 shares issued
and outstanding at June 30, 2026 and
December 31, 2025, respectively
5
5
Additional paid-in capital
1,266,004
1,229,442
Accumulated other comprehensive loss
(875)
(687)
Accumulated deficit
(1,193,369)
(1,126,027)
Total stockholders' equity
71,765
102,733
Total liabilities and stockholders' equity
$
386,618
$
453,032
REGENXBIO INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
(unaudited)
(in thousands, except per share data)
Three Months
Six Months
Ended June 30,
Ended June 30,
2026
2025
2026
2025
Revenues
License and royalty revenue
$
103,841
$
18,465
$
108,931
$
105,514
Service revenue
4,178
2,894
5,481
4,857
Total revenues
108,019
21,359
114,412
110,371
Operating Expenses
Cost of license and royalty revenues
1,042
5,209
12,116
8,645
Research and development
56,086
59,500
113,425
112,587
General and administrative
21,616
19,883
42,922
40,230
Other operating expenses
12
45
48
60
Total operating expenses
78,756
84,637
168,511
161,522
Income (loss) from operations
29,263
(63,278)
(54,099)
(51,151)
Other Income (Expense)
Interest income from licensing
17
21
33
46
Investment income
1,222
3,379
3,225
5,880
Interest expense
(7,793)
(10,993)
(16,501)
(19,563)
Total other income (expense)
(6,554)
(7,593)
(13,243)
(13,637)
Net income (loss)
$
22,709
$
(70,871)
$
(67,342)
$
(64,788)
Other Comprehensive Income (Loss)
Unrealized gain (loss) on available-for-sale securities, net
(5)
12
(188)
(9)
Total other comprehensive income (loss)
(5)
12
(188)
(9)
Comprehensive income (loss)
$
22,704
$
(70,859)
$
(67,530)
$
(64,797)
Net income (loss) per share:
Basic
$
0.43
$
(1.38)
$
(1.28)
$
(1.26)
Diluted
$
0.43
$
(1.38)
$
(1.28)
$
(1.26)
Weighted-average common shares outstanding:
Basic
52,820
51,483
52,625
51,423
Diluted
53,016
51,483
52,625
51,423
SOURCE REGENXBIO Inc.